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EXPERT OPINION
Abstract: Ziconotide is a powerful analgesic drug that has a unique mechanism of action
involving potent and selective block of N-type calcium channels, which control
neurotransmission at many synapses. The analgesic efficacy of ziconotide likely results from
its ability to interrupt pain signaling at the level of the spinal cord. Ziconotide is a peptidic
drug and has been approved for the treatment of severe chronic pain in patients only when
administered by the intrathecal route. Importantly, prolonged administration of ziconotide
does not lead to the development of addiction or tolerance. The current review discusses the
various studies that have addressed the in vitro biochemical and electrophysiological actions
of ziconotide as well as the numerous pre-clinical studies that were conducted to elucidate its
antinociceptive mechanism of action in animals. In addition, this review considers the pivotal
Phase 3 (and other) clinical trials that were conducted in support of ziconotide’s approval for
the treatment of severe chronic pain and tries to offer some insights regarding the future
discovery and development of newer analgesic drugs that would act by a similar mechanism
to ziconotide but which might offer improved safety, tolerability and ease of use.
Keywords: ziconotide; Prialt; analgesic drug; N-type calcium channel blocker; severe chronic
pain
Introduction
Ziconotide, which is also known as SNX-111, is a novel non-opioid analgesic drug.
It is a synthetic version of ω-conotoxin MVIIA (ω-MVIIA), which is a peptide that
is found in the venom of the fish-eating marine snail, Conus magus. Ziconotide has
only limited ability to cross the blood–brain barrier and so in order to achieve optimal
analgesic efficacy with reduced potential for serious side-effects, it must be
administered intrathecally to patients. This spinal route of administration permits
ziconotide to reach its maximum local concentration in a short time, which encourages
a rapid onset of analgesia. Following the successful completion of three pivotal double-
blind, placebo-controlled trials, intrathecal infusion of ziconotide was recently
approved by regulatory bodies worldwide as a therapeutic approach for the
symptomatic management of severe chronic pain, particularly in patients who are
refractory to treatment with morphine and for whom intrathecal therapy is a viable
option. The “Ziconotide Intrathecal Infusion” product is marketed by Elan
Pharmaceuticals as Prialt
® and is intended for continuous delivery via a programmable
surgically implanted variable rate infusion device such as the Medtronic SynchroMed®
EL, the SynchroMed
® II Infusion System, or the CADD-Micro
® Ambulatory Infusion
Pump. Alternatively, an external microinfusion device can be used temporarily. The
use of an infusion pump allows the dose of ziconotide to be titrated incrementally
according to patients’ personal needs and comfort in order to achieve an optimal
balance of analgesic efficacy and side-effects.
Ziconotide’s pharmacological effects have been investigated extensively in pre-
clinical in vivo and in vitro models. Briefly, intrathecal ziconotide is a powerful
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antinociceptive drug in several animal models of chronic
pain and it appears to have a completely novel mechanism
of action that involves potent and selective block of pre-
synaptic neuronal N-type calcium channels in the spinal
cord. In fact, it is the only selective N-type channel blocker
that is currently approved for clinical use. Evidence suggests
that ziconotide delivers its antinociceptive efficacy by
reducing the release of pronociceptive neurotransmitters in
the dorsal horn of the spinal cord, thereby inhibiting pain
signal transmission. Intrathecal ziconotide’s clinical efficacy
is consistent with the hypothesis that spinal N-type calcium
channels are key regulators of nociceptive signaling in
humans, although it is fair to say that its precise analgesic
mechanism in humans remains unconfirmed at this time.
There are several recent publications that are relevant to
the topics in this review and they will be cited where
appropriate.
Acute and chronic pain
Pain has been defined as “an unpleasant sensory and
emotional experience that is associated with actual or
potential tissue damage” (International Association for the
Study of Pain
®) and can be classified according to a variety
of characteristics including its duration (acute or chronic)
and intensity (mild, moderate, or severe). Acute pain is a
normal experience that is usually short-lasting and serves
to alert the body about ongoing tissue damage so that
protective or evasive measures can be taken. Acute pain
usually lessens over time as a consequence of the healing
process. In contrast, chronic pain represents an abnormal
experience that is long-lasting and persists in the absence
of any apparent tissue damage. Chronic pain is not
equivalent to long-lasting acute pain; it appears to serve no
useful purpose and is often associated with diseases
involving tissue inflammation (leading to chronic
inflammatory pain) or damage to peripheral or central
neurons (leading to chronic neuropathic pain). More
complex chronic pain syndromes may exhibit signs of both
inflammatory and neuropathic pain.
Pain is experienced through a complex neural network
that has two anatomically defined and functionally
interacting systems that control pain perception and pain
modulation (Almeida et al 2004; Apkarian et al 2005).
During normal pain sensation, components of the pain
perception system are activated first and subsequently the
pain modulation system may contribute inhibitory and/or
facilitatory input to alter the strength and duration of the
pain. During pain perception, the peripheral nerve endings
of high-threshold mechanosensitive and polymodal
nociceptive neurons, whose cell bodies are located in the
dorsal root ganglia (DRG), are excited by noxious stimuli,
leading to the generation and propagation of sodium
channel-dependent action potentials along small diameter
finely myelinated (Aδ fiber) or unmyelinated (C fiber)
axons. The Aδ and C fibers project mainly to the superficial
laminae of the dorsal horn in the spinal cord, where they
make synaptic connections with secondary sensory neurons
(Light and Perl 1979a, 1979b; Light et al 1979). In contrast,
large diameter low-threshold mechanosensitive Aβ fibers,
which encode ordinary tactile information, project mainly
to the deeper laminae of the dorsal horn. When the action
potentials reach the central terminals of the primary afferent
neurons, calcium influx through pre-synaptic voltage-gated
calcium channels triggers the release of pronociceptive
neurotransmitters and neuromodulators such as substance
P, calcitonin gene related peptide (CGRP), and glutamate
(Levine et al 1993; Dickenson et al 1997; Bennett 2000).
Under conditions of chronic pain, plastic changes in the
nervous system may occur, possibly leading to overactivity
in the pain perception system and/or an imbalance in the
inhibitory and facilitatory components of the pain
modulation system. Both peripheral and central maladaptive
mechanisms may contribute to the generation of sensory
deficits (Katz and Rothenberg 2005). Peripheral mechanisms
include sensitization of Aδ and C fibers, phenotypic
switching of Aβ fibers, and awakening of silent nociceptors.
Central mechanisms include sensitization of secondary and
tertiary sensory neurons, as well as spinal and cortical circuit
reorganization.
Many medications are available to treat acute and chronic
inflammatory pain, but options for treating chronic
neuropathic pain are more limited. Mild to moderate acute
pain often can be managed effectively by over-the-counter
medications, such as acetaminophen, whereas severe acute
pain requires stronger analgesics such as opioid drugs. The
exact mechanism of action of acetaminophen is unknown
and although it is a very safe drug with few side-effects, a
recent study suggests that it may increase the serum levels
of liver enzymes when taken at high doses (Watkins et al
2006). The opioid drugs are very effective pain relievers
and exert their analgesic effects by agonizing μ, δ, and κ
opioid receptors located at spinal and supraspinal sites in
the central nervous system. Unfortunately, the opioids can
produce serious side-effects, are prone to addiction and
promote the development of tolerance with prolonged or
repeated use. Drugs that have been used to treat painNeuropsychiatric Disease and Treatment 2007:3(1) 71
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associated with inflammation include non-steroidal anti-
inflammatory drugs (NSAIDs), such as ibuprofen and
naproxen. These drugs are non-selective inhibitors of the
two major isoforms of cyclo-oxygenase (COX), ie,
constitutive COX-1 and inducible COX-2. The COX
inhibitors work by decreasing the production of
prostaglandins, which are endogenous agents that are known
to sensitize peripheral and central sensory neurons
(McMahon et al 2005). However, these non-selective drugs
are associated with the development of gastric ulcers,
probably as a result of COX-1 inhibition. In contrast, COX-
2 selective inhibitors produce fewer gastrointestinal
problems and were prescribed widely for several years, but
following controversial revelations regarding potential
cardiovascular risks, some COX-2 inhibitors have been
withdrawn from the market and others now carry warnings
about the potential dangers. Drugs that have been approved
for the treatment of neuropathic pain include carbamazepine,
gabapentin, pregabalin and duloxetine. In addition, several
tricyclic antidepressant, antiepileptic, and antiarrhythmic
drugs are commonly used off-label for the symptomatic
relief of neuropathic pain. The majority of these drugs appear
to act by inhibiting non-selectively the activity of neuronal
voltage-gated sodium and calcium channels. However, these
drugs usually require high doses, have a high incidence of
non-responders and deliver suboptimal efficacy.
Consequently, there are significant opportunities for the
discovery and development of novel drugs for the treatment
of severe and chronic pain conditions although it must be
remembered that regulatory agencies will insist that drugs
are very safe before granting market approval.
Voltage-gated calcium channels,
neurotransmission, and pain signaling
Various subtypes of voltage-activated calcium-permeable
ion channels, including L-type, N-type, P/Q-type, and T-
type channels have been identified throughout the
mammalian nervous system. Most neuronal voltage-
activated calcium channels are believed to exist as a complex
of proteins (see Figure 1), comprising a large α1 subunit,
which forms the pore of the channel and is responsible for
defining the majority of its biophysical and pharmacological
properties, as well as smaller auxiliary disulphide-linked
α2δ and cytosolic β subunits, which regulate membrane
insertion of the channel complex and modulate its functional
properties (Arikkath and Campbell, 2003). So far 10
architecturally similar α1 subunits have been identified and
structural elements have been identified that correlate with
certain functions of the channel (Ertel et al 2000; Catterall
et al 2003). The α1 subunit is organized into four
homologous domains (DI-DIV), each of which contains six
membrane-spanning segments (S1-S6). Membrane
depolarization is sensed by positively charged amino acids
in the so-called voltage-sensors that are located in the S4
transmembrane segment of each domain. The selectivity of
the channel for calcium and the process of ion permeation
are governed by four critical glutamate residues, one in each
of the pore loops (P-loops) that are located between the S5
and S6 segments in each domain of the α1 subunit (Sather
and McCleskey 2003). Of relevance to the current review,
the molecular target of ziconotide appears to be the N-type
calcium channel, which is a high-voltage-activated channel
that contains the α1B subunit (also known as CaV2.2). The
α1B subunit is subject to extensive splice variation (Lin et
al 1997, 1999; Meadows and Benham 1999; Pan and
Lipscombe 2000; Bell et al 2004; Castiglioni et al 2006),
which enhances not only the molecular diversity of the N-
type calcium channel but also its functional diversity, since
there is the potential for altered biophysical and
pharmacological properties. Perhaps with the exception of
the α2δ subunit, which binds gabapentin and pregabalin,
Figure 1 Schematic representation of the putative structure of the voltage-
gated N-type calcium channel. N-type calcium channels are made up of a large
pore-forming a1B subunit in association with one or more auxiliary subunits. The
a1B subunit contains most determinants of channel function, including its
biophysical and pharmacological properties. The proposed membrane topology
of the a1B subunit is believed to involve four homologous domains (DI-DIV),
each of which contains six transmembrane segments (S1-S6; not shown). The
auxiliary subunits include the disulphide-linked a2d subunit, which is anchored in
the membrane by a single membrane-spanning segment and the cytosolic b
subunit, which interacts with the intracellular loop connecting DI to DII in the
a1B subunit.
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the α1B subunit contains most of the pharmacologically
relevant binding sites on the N-type calcium channel.
Calcium permeation can be modulated by agents that directly
block the pore of the channel, such as divalent cations and
peptides derived from venomous species, as well as by small
molecule drugs that block the channel in a use-dependent
manner, as a result of preferential interactions with activated
and/or inactivated states of the channel (Winquist et al 2005).
Voltage-activated calcium channels exhibit subtype-
specific cellular and subcellular distributions in the nervous
system and play distinct roles in controlling neuronal
physiology. For instance, pre-synaptic calcium channels play
a critical role in the biochemical cascade of events that leads
to the exocytotic release of neurotransmitters via fusion of
synaptic vesicles with the plasma membrane
(Schneggenburger and Neher 2005). Immunocytochemical
approaches have revealed that N-type and P/Q-type calcium
channels are localized predominantly on pre-synaptic nerve
terminals throughout the nervous system (Westenbroek et
al 1998), where they associate with and are regulated by
other components of the cellular machinery involved in
synaptic transmission (Zhong et al 1999; Zamponi 2003).
Although both subtypes are found pre-synaptically on the
terminals of primary sensory neurons in the dorsal horn,
only occasionally are they co-localized on the same nerve
terminal (Westenbroek et al 1998). The N-type channels
are evenly distributed throughout all the laminae of the
dorsal horn and are in fact the predominant subtype in the
superficial laminae (1 and 2), which is consistent with an
involvement in Aδ and C fiber-mediated pain signaling
(Gohil et al 1994). Furthermore, N-type channels are
exclusively co-localized with substance P in presumptive C
fiber terminals (Westenbroek et al 1998). In contrast, the P/
Q-type channels are not found in lamina 1 of the dorsal
horn, although their presence in lamina 2 suggests that they
may also play a role in pain signal processing.
 In accordance with these distribution data, the use of
subtype-selective calcium channel blockers has confirmed
that synaptic transmission in the peripheral and central
nervous systems is triggered mainly by calcium influx
through N-type and P/Q-type channels (Gaur et al 1994;
Wheeler et al 1994; Mintz et al 1995), although additional
subtypes may also contribute but to a lesser degree
(Gasparini et al 2001). In the spinal cord, N-type and P/Q-
type calcium channels contribute to both excitatory and
inhibitory synaptic transmission. Interestingly, the N-type
calcium channel is subject to direct regulation by G-protein
βγ subunits (De Waard et al 2005) and a component of the
spinal analgesic action of opioid drugs likely involves
reduced release of pronociceptive neurotransmitters in the
dorsal horn as a consequence of μ-opioid receptor activation
and G-protein-dependent inhibition of N-type channels
(North 1986). The importance of both N-type and P/Q-type
calcium channels in the transmission and modulation of
nociceptive signaling at the level of the spinal cord is further
supported by in vivo pharmacological experiments with
subtype-selective blockers, which will be discussed in more
depth later (Chaplan et al 1994; Malmberg and Yaksh 1994;
Diaz and Dickenson 1997; Matthews and Dickenson 2001).
In addition, the reader is directed to several recent reviews
that have discussed the relative contributions of N-type and
other calcium channel subtypes to pain signaling (McGivern
and McDonough 2004; McGivern 2006; Yaksh 2006).
Ziconotide: structural
considerations and in vitro
biochemical and
electrophysiological studies
The ω-conotoxins, such as  ω-GVIA, ω-MVIIA, ω-MVIIC,
and ω-CVID, constitute a structurally related group of
polypeptidic molecules that are found naturally in the venom
of certain species of marine snail. In general, the ω-
conotoxins bind with high affinity to voltage-gated calcium
channels and potently block calcium flux. Despite structural
conservation not only among the various ω-conotoxins but
also among their binding sites on voltage-activated calcium
channels, individual peptides actually exhibit distinguishing
specificities for different channels.
ω-MVIIA contains 25 amino acids, 6 of which are
cysteine residues that are linked in pairs by 3 disulphide
bonds (see Figure 2A). The disulphide bond linkage pattern
is a characteristic feature of ω-conotoxins and serves to
ensure correct folding of the peptide and stabilization of its
structure in a compact, well-defined, native conformation
(Chung et al 1995). Disruption of any one of the disulphide
bridges greatly destabilizes the structure of ω-MVIIA and
renders the remaining disulphide bonds more prone to
reduction. Interestingly, the naturally occurring ω-MVIIA
is synthesized by Conus magus as a precursor peptide that
includes a C-terminally located glycine residue that becomes
post-translationally converted to an amide group. This
glycine appears to enhance the folding efficiency of the
peptide in vivo by promoting molecular interactions that
stabilize the native conformation with respect to other
disulphide-bonded forms (Price-Carter et al 1996; Price-Neuropsychiatric Disease and Treatment 2007:3(1) 73
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Carter et al 1998). The high resolution three dimensional
structure of w-MVIIA has been determined by nuclear
magnetic resonance (NMR) spectroscopy. The molecule
displays a short triple-stranded anti-parallel β-sheet structure
containing four loops, as illustrated in Figure 2B (Basus et
al 1995; Kohno et al 1995).
As already mentioned, the molecular target of ziconotide
(ω-MVIIA) appears to be the N-type calcium channel. In
support of this hypothesis, radioligand binding experiments
have demonstrated that ziconotide binds rapidly, reversibly,
and with high affinity (see Table 1A) to N-type calcium
channels in membrane and synaptosome preparations of rat
brain (Stoehr and Dooley 1993; Kristipati et al, 1994).
Ziconotide displays a high degree of binding and functional
selectivity (>1000-fold) for the N-type calcium channel
(Olivera et al 1987; Nielsen et al 1999b; Lewis et al 2000),
whereas in contrast ω-MVIIC is more selective for the P/
Q-type calcium channel (Hillyard et al 1992). It is believed
that the differential potencies of the toxins are determined
largely by the relative positions of amino acid side chains
on the exposed surface of the toxin peptides (Nielsen et al
1996). In the case of ω-MVIIA, it is the non-cysteine amino
Figure 2 Putative structure of ziconotide.
C-K-G-K-G-A-K-C-S-R-L-M-Y-D-C-C-T-G-S-C-R-S-G-K-C
A.  Amino acid sequence of  -MVIIA, illustrating the characteristic disulphide linkage 
pattern between the six cysteine residues. The three disulphide bridges serve to 
stabilize the native conformation of the toxin and cause the peptide to display 4 loops, 
some of which contain important structural determinants of N-type calcium channel 
blocking activity, eg, tyrosine-13 (in bold). 
B.  Representation of the 3-dimensional structure of  -MVIIA. The coordinates of  -
MVIIA were obtained from the Protein Data Bank (http://www.rcsb.org/) entry 1OMG. 
The position of the critical residue tyrosine-13 is indicated. (The assistance of Les 
Miranda, Peptide Research & Discovery, Amgen Inc. is gratefully acknowledged in 
generating Figure 2B.) 
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Table 1 Summary of in vitro studies with ziconotide
A. Radioligand binding studies
N-type calcium channels in rat brain membranes or Saturation binding of 
125I-w-MVIIA
synaptosomes - Kd 1.1 pM (Stoehr and Dooley 1993)
-K d 9 pM (Kristipati et al 1994)
Kinetic analysis of binding of 
125I-w-MVIIA
-K d 7 pM (Stoehr and Dooley 1993)
-K d 18 pM (Kristipati et al 1994)
Displacement of 
125I-w-MVIIA
-K i 1 pM (Kristipati et al 1994)
-I C 50 2 pM (Newcomb et al 1995)
-I C 50 7.2 pM (Wang et al 1998)
-I C 50 29 pM (Lewis et al 2000)
Displacement of 125I-w-GVIA
-I C 50 45 pM (Nielsen et al 1999b)
-I C 50 55 pM (Lewis et al 2000)
B. Electrophysiological studies
Inhibition of native high-voltage-activated calcium currents Human neuroblastoma, IMR32 cells
- 42% inhibition of total calcium current at 10 nM (Fox 1995)
Rat superior cervical ganglion neurons
-I C 50 32 nM, with 90% inhibition (Sanger et al 2000)
Rat hippocampal neurons
- 30% inhibition of total calcium current at 3 μM (Wen et al 2005)
Inhibition of recombinant a1B-mediated calcium currents Human a1B
- HEK cells, 92% inhibition at 100 nM (Bleakman et al 1995)
Rat a1B
- HEK cells, IC50 72 nM (Sanger et al 2000)
- tsa-201 cells, complete block by 100 nM (Feng et al 2001)
- Xenopus oocytes, IC50 0.4-11 nM, depending on the a1B splice variant and
the absence or presence of the b3 subunit (Lewis et al 2000)
C. Neurotransmitter release studies
Depolarization-evoked norepinephrine release Rat hippocampus
-I C 50 ~0.5 nM (Newcomb et al 1995)
-I C 50 5.5 nM (Wang et al 1998)
Rat peripheral sympathetic efferent neurons
-I C 50 1.2 nM (Wang et al 1998)
Depolarization-evoked substance P release Rat dorsal root ganglion neurons
-I C 50 63 nM (Smith et al 2002)
acids in the loops that determine its binding affinity and
calcium-channel-blocking activity. In particular, the second
loop located between cysteine-8 and cysteine-15 appears to
be most important in directing the selectivity of ω-MVIIA
towards N-type channels and away from P/Q-type channels,
although the fourth loop also contributes to a lesser degree
(Nielsen et al 1999b). Alanine substitution experiments have
revealed that tyrosine-13 in ω-MVIIA is a critical
determinant of binding to N-type calcium channels (Kim et
al 1995). As one would expect, correct folding of the ω-
MVIIA peptide is necessary to ensure appropriate
positioning of tyrosine-13 and permit toxin binding to the
N-type calcium channel (Kohno et al 1995). Furthermore,
altering the chirality of tyrosine-13 appears to affect the
positions of key residues in the second loop of ω-MVIIA,
leading to a reduction in its ability to recognize the N-type
calcium channel in a radioligand binding assay (Nielsen et
al 1999a). In addition, individual amino acid substitutions
and chimeric-toxin approaches have revealed the importance
of other amino acids such as lysine-2 and arginine-21 as
well as those residues in positions 9 through 12 in
determining the binding of ω-MVIIA to the N-type calcium
channel (Nadasdi et al 1995; Sato et al 1997, 2000).
Ziconotide appears to bind to the pore region of the α1B
subunit and may interfere with calcium permeation by
physically occluding the channel. Electrophysiological
experiments have demonstrated conclusively that ziconotide
inhibits N-type calcium currents in native cells as well as in
heterologous expression systems (see Table 1B). Most native
cells express a variety of different calcium channels and asNeuropsychiatric Disease and Treatment 2007:3(1) 75
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a result, ziconotide only partially reduces high-voltage-
activated calcium currents in differentiated human
neuroblastoma IMR32 cells (Fox 1995), rat superior cervical
ganglion neurons (Sanger et al 2000), and rat hippocampal
neurons (Wen et al 2005). Ziconotide also reduces calcium
currents that result from expression of the α1B subunit in
HEK cells (Bleakman et al 1995; Sanger et al 2000), tsa-
201 cells (Feng et al 2003), and Xenopus laevis oocytes
(Newcomb et al 1995; Lewis et al 2000; Luchian 2001).
Mechanistically, ziconotide exhibits little or no use-
dependence in its inhibitory effect, which probably reflects
its equal binding affinity for resting, open, and inactivated
states of the channel (Feng et al 2003). Interestingly, the
inhibitory potency of ziconotide on α1B-mediated calcium
currents may vary depending on whether or not α2d and/or
β auxiliary subunits are co-expressed (Lewis et al 2000;
Luchian 2001; Mould et al 2004).
Chimeric-calcium channel α1 subunit approaches along
with amino acid substitution experiments have shed light
on which regions of the large α1B subunit may define the
binding site and determine the characteristics of block by
ziconotide. The binding site for ziconotide appears to be
overlapping with that of ω-GVIA, which is positioned close
to the P-loop of DIII (Ellinor et al 1994). Notably, the α1B
subunit contains an EF hand-like motif that is located close
to the P-loop in DIII. This EF hand-like motif may serve to
bind calcium and facilitate its permeation through the pore
of the channel. In addition, this motif may also impact ω-
conotoxin binding. Indeed, electrophysiological experiments
have revealed that mutations at glycine-1326 and glutamate-
1332 affect not only calcium permeation but also the channel
blocking characteristics of ω-MVIIA. In particular, glycine-
1326 appears to restrict access of the toxin to its binding
site, thereby decreasing the rate of onset of block and
enhancing the reversibility of block (Feng et al 2001).
Interestingly, calcium channel block by ziconotide and ω-
GVIA are affected differently by amino acid mutations
downstream of the EF hand-like motif, supporting the idea
that their respective binding sites are overlapping but not
identical (Feng et al 2003).
Since it blocks N-type calcium channels so potently,
ziconotide has proven to be an effective inhibitor of
neurotransmitter release at multiple synapses in the nervous
system (see Table 1C). In fact due to its subtype-specificity,
ziconotide is often used as a tool to define the contribution
of N-type calcium channels to synaptic transmission at
central and peripheral synapses. Thus ziconotide inhibits
norepinephrine release from hippocampal (Newcomb et al
1995; Wang et al 1998) and peripheral sympathetic efferent
neurons (Wang et al 1998). Consistent with the co-
localization of N-type calcium channels and substance P in
the central nerve terminals of primary afferent neurons
(Westenbroek et al 1998), ziconotide potently inhibits the
depolarization-evoked release of substance P from spinal
cord slices (Smith et al 2002). This result implicates N-type
calcium channels in the central processing of pain signals
and suggests that this mechanism may contribute to the
antinociceptive efficacy of ziconotide. Due to the
predominant role of P-type calcium channels in controlling
neurotransmitter release at the neuromuscular junction
(Llinas et al 1992), ziconotide does not inhibit most nerve-
evoked muscle contractions (Bowersox et al 1995).
Ziconotide: pre-clinical in vivo
studies
Ziconotide has been described as a potent and long-lasting
antinociceptive drug when administered by the intrathecal
route. Experimental evidence of ziconotide’s antinociceptive
properties was first obtained in the early 1990s and since
then extensive studies have been conducted to characterize
its effects in multiple animal models of pain (see Tables 2
and 3 for details on efficacy and dosing). These studies have
revealed that ziconotide is more potent than morphine and
is particularly efficacious in models of persistent pain
(duration measured in minutes to hours) and chronic pain
(duration measured in hours to days). In comparison, it tends
to be less effective in tests of acute pain (duration measured
in minutes). It is also important to note that ziconotide can
be efficacious under a variety of intrathecal dosing regimens,
including single bolus injection and acute or chronic
continuous infusion. Despite its potent efficacy, the
therapeutic index of spinal ziconotide tends to be low and
often its antinociceptive effects in animals are accompanied
by motor deficits at higher doses. Although ziconotide does
not easily cross the blood brain barrier in normal animals, it
may cause hypotension if it enters the systemic circulation
(Bowersox et al 1992; Wright et al 2000; Takahara et al
2002). This effect on blood pressure appears to be mediated
at least partially by inhibition of sympathetic
neurotransmission, probably as a result of N-type calcium
channel blockade in sympathetic nerve terminals (Wang et
al 1998).
Formalin is a chemical irritant that when injected
subcutaneously into the rat paw evokes a complex
behavioral response consisting of an early (acute) phase and
a late (persistent) phase of paw flinching and licking. ThisNeuropsychiatric Disease and Treatment 2007:3(1) 76
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biphasic behavioral response appears to be correlated
temporally with formalin-evoked electrical activity in both
primary afferents and secondary sensory neurons in the
dorsal horn of the spinal cord (Dickenson and Sullivan
1987b). Electrophysiological experiments have revealed an
initial period of high intensity C fiber firing, which is
followed by a prolonged period of lower intensity C fiber
discharging accompanied by facilitation (“wind up”) of
dorsal horn neuronal responses. The early phase of neuronal
firing appears to be due to the direct excitation of peripheral
C fiber nerve endings by formalin (Dickenson and Sullivan
1987a), whereas the late phase, although dependent on the
early phase for its induction, appears to require additionally
the release of pronociceptive neurotransmitters and
activation of post-synaptic N-methyl-D-aspartate (NMDA)
subtype of glutamate receptors in the spinal cord (Haley et
al 1990).
Consistent with their predominant role in controlling
release of pronociceptive neurotransmitters in the dorsal
horn, N-type calcium channels appear to be involved in
defining both the electrophysiological and behavioral
responses to peripheral injection of formalin (Malmberg and
Yaksh 1994; Diaz and Dickenson 1997). In common with
other ω-conotoxins such as ω-GVIA, ziconotide suppresses
the formalin-induced hyperexcitability of dorsal horn
neurons (Diaz and Dickenson 1997). These
electrophysiological effects are consistent with the ability
of the ω-conotoxins to exert antinociceptive effects in the
formalin model (see Table 2A), as assessed during both
phases of the behavioral response (Malmberg and Yaksh
Table 2 Summary of experiments conducted with ziconotide in rat behavioral models of acute pain (all dosing was intrathecal)
A. Formalin model studies
5%-formalin injected into the paw Phase 1 Response Phase 2 Response
Bolus injection Bolus injection
(Malmberg and Yaksh 1994) - ID50 3 pmol - ID50 3 pmol
(Bowersox et al 1996) - No significant effect - 100 ng caused ∼50% decrease 
(Wang et al 2000a) - No significant effect - ID50 110 ng
(Malmberg and Yaksh 1995) 2-day infusion 2-day infusion
-3  pmol/h →42.5% decrease - 3 pmol/h →42.7% decrease
-3 0  pmol/h →61.2% decrease - 30 pmol/h →86.0% decrease
(Bowersox et al 1996) 3-day infusion 3-day infusion
-I D 50 14 ng/h - ID50 0.82 ng/h
(Malmberg and Yaksh 1995) 7-day infusion 7-day infusion
-3  pmol/h →20.4% decrease - 3 pmol/h →59% decrease
-3 0  pmol/h →43.1% decrease - 30 pmol/h →86.1% decrease
B. Other acute pain studies
Paw incision Bolus injection
(Wang et al 2000b) - 1 h pre-incision:1 μg prevented mechanical allodynia and heat hyperalgesia
-1  d post-incision: mechanical allodynia ID50 <0.3 μg and heat hyperalgesia ID50 0.1 μg
52.5°C hot plate Bolus injection
(Malmberg and Yaksh 1994) - 20% increase in paw withdrawal latency at 8 pmol 
(Wang et al 2000a) - 22% increase in paw withdrawal latency at 30 ng/h 
Continuous infusion
(Malmberg and Yaksh 1995) - 3 pmol/h →approximately doubled the paw withdrawal latency following 2-day and 7-day
infusion
-3 0  pmol/h →approximately tripled the paw withdrawal latency following 2-day and 7-day
infusion
Paw pressure (analgesymeter) Bolus injection
(Wang et al 2000a) - ID50 0.6 μg
Tail flick (infra-red heat) Bolus injection
(Scott et al 2002) - No significant effect at 0.3-1.0 μg/kg
Tail immersion (50°C water) Continuous infusion
(Wang et al 2000a) - 0.03 μg/h →no significant effect following 7-day infusionNeuropsychiatric Disease and Treatment 2007:3(1) 77
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1994, 1995; Bowersox et al 1996; Wang et al 2000a; Chen
et al 2005). The antinociceptive efficacy of ziconotide can
be observed under a variety of dosing regimens including
administration prior to the injection of 5% formalin, either
as single bolus injection (eg, 10 minutes before) or following
acute (up to 2 days before) or chronic (up to 7 days before)
continuous infusion. In general ziconotide is more
efficacious when administered prophylactically, although
it does have activity in the late phase of the behavioral
response when administered 9 minutes after the injection
of formalin. Overall, ziconotide appears to be more effective
at inhibiting the late phase rather than the early phase of the
behavioral response to formalin. Perhaps consistent with
its lesser effects in the early phase of the formalin test,
ziconotide is not very effective at increasing pain thresholds
in more straightforward models of acute pain (see Table
2B), such as the hot plate, radiant heat, and tail immersion
tests in rats (Malmberg and Yaksh 1994, 1995; Wang et al
2000a, 2000b; Scott et al 2002).
The antinociceptive efficacy of ziconotide was also
studied in animal models of inflammatory pain and nerve
injury-evoked pain. Typically, animal models of
inflammatory pain employ biochemical agents to sensitize
or activate primary afferent neurons, leading to spontaneous
pain as well as hyperresponsiveness to noxious
(hyperalgesia) and innocuous (allodynia) stimuli. On the
other hand, animal models of nerve injury-evoked pain
usually involve constriction, ligation or partial transection
of a peripheral or spinal nerve, leading to the development
of behavioral symptoms that mimic some of the sensory
abnormalities that are reported by neuropathic pain patients.
These sensory phenomena include hyperalgesia and
allodynia, both of which can be assessed behaviorally and
interpreted as symptoms of neuropathic-like pain.
Ziconotide exerts potent antihyperalgesic and antiallodynic
effects in models of acute and chronic inflammatory pain
(see Table 3-A) and in models of neuropathic pain (see Table
3-B). In a model of acute inflammatory pain, intrathecal
ziconotide is able to prevent (infusion initiated 1 hour before
biochemical challenge) or reverse (continuous infusion
initiated 4 hours after biochemical challenge) kaolin and
carrageenan-induced secondary heat hyperalgesia in the
knee joint (Sluka 1998). In a rat incisional model of post-
operative pain, a single bolus injection of ziconotide is able
to reverse established heat hyperalgesia and mechanical
allodynia (Wang et al 2000b) and in a model of chronic
inflammatory pain, an intrathecal bolus of ziconotide can
reverse Freund’s complete adjuvant-induced mechanical
hyperalgesia in the hind paw (Smith et al 2002). In models
of neuropathic pain, including several that involve
surgically-induced damage to the sciatic nerve or spinal
nerve roots, ziconotide is effective at reversing established
hyperalgesia and allodynia, either when administered by
bolus injection or by continuous spinal infusion (Chaplan
Table 3 Summary of experiments conducted with ziconotide in rat behavioral models of chronic pain (all dosing was intrathecal)
A. Inflammatory pain studies
Kaolin (3%) and carrageenan (3%)
injected into the knee-joint Continuous infusion
(Sluka 1998) - 1 h infusion pre-induction:  100 μM at 5 μL/min. prevented the development of
secondary heat hyperalgesia
- Continuous infusion beginning 4 h post-induction: 100 μM at 5 μL/min.
reversed established secondary heat hyperalgesia within 1 h
Complete Freund’s adjuvant (CFA)
injected into the paw Bolus injection
(Smith et al 2002) - 5 days post-CFA injection: ID50 16 pmol
B. Neuropathic Pain Studies
Spinal nerve (L5/L6) ligation Bolus injection
(Chaplan et al 1994) - Mechanical allodynia: ID50 1000 ng
(Bowersox et al 1996) - Mechanical allodynia: ID50 30-100 ng
(Scott et al 2002) - Mechanical allodynia: ID50 320 ng/kg
Continuous infusion
(Bowersox et al 1996) - Mechanical allodynia: ID50 10 ng/h following 3-day infusion
Chronic constriction injury (sciatic) Bolus injection
(Yamamoto and Sakashita 1998) - Heat hyperalgesia: 100 pmol reversed heat hyperalgesia
Partial nerve injury (sciatic) Bolus injection
(Yamamoto and Sakashita 1998) - Heat hyperalgesia: no significant effect on heat hyperalgesia at 100 pmolNeuropsychiatric Disease and Treatment 2007:3(1) 78
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et al 1994, Bowersox et al 1996; Yamamoto and Sakashita
1998; Scott et al 2002; Urban et al 2005). Interestingly,
ziconotide can also be efficacious when administered outside
the spinal cord. For instance, significant antihyperalgesic
and antiallodynic effects have been observed following local
application of ziconotide (ID50 <1.0 μg) to the site of sciatic
nerve injury in rats (Xiao and Bennett 1995). Additionally,
antiallodynic effects can be produced following
microinjection of ziconotide (ID50 2.8 pmol) into the rostral
ventromedial medulla in rats with spinal nerve ligation
(Urban et al 2005), presumably by inhibiting
neurotransmitter-dependent activation of pain facilitatory
neurons that, by way of their descending projections to the
dorsal horn of the spinal cord, contribute to the maintenance
of hypersensitivity in neuropathic pain states (Ossipov et al
2000; Porreca et al 2001).
The anti-nociceptive efficacy of ziconotide in animal
models of pain is obviously complex. Nevertheless, the
results described above are particularly enlightening with
respect to both the mechanism of action of ziconotide and
the role of N-type calcium channels in controlling pain signal
transmission. The differential efficacy of ziconotide in
models of acute versus persistent pain may reflect changes
in the expression level of calcium channel subunits under
conditions of neuronal hyperexcitability. Both the α1B and
α2δ subunits appear to be up-regulated in response to tissue
inflammation or nerve injury (Luo et al 2001; Newton et al
2001; Abe et al 2002; Cizkova et al 2002; Yokoyama et al
2003). Consequently, N-type calcium channels might
become functionally more important in hypersensitive states
and their role in pain transmission could be greater under
conditions of ongoing chronic pain rather than under
conditions of acute pain. Alternatively, it is known that the
pharmacology of the N-type calcium channel can change
depending on its subunit composition, at least in
heterologous expression systems (Lewis et al 2000; Luchian
2001; Mould et al 2004). If this mechanism were to be
replicated in native neuronal N-type calcium channels,
then tissue inflammation- or nerve injury-induced
alterations in the subunit composition of the channels
could lead to increased sensitivity to ziconotide’s
blocking actions.
The antinociceptive profile of ziconotide in models of
acute, persistent and chronic pain is worthy of comparison
with that of P/Q-type calcium channel blockers, such as ω-
agatoxin-IVA. The potency and efficacy of ziconotide
suggests that although N-type calcium channels in the pain
pathway contribute to the perception of acute pain (eg, first
phase of the formalin test as well as the hot plate test), they
play a more significant role in the development and
maintenance of multiple hypersensitive painful states (eg,
second phase of the formalin test as well as inflammatory
and neuropathic pain models). In contrast, the
antinociceptive profile of ω-agatoxin-IVA suggests that P/
Q-type calcium channels contribute only to inflammation-
associated painful conditions (Malmberg and Yaksh 1994;
Diaz and Dickenson 1997; Nebe et al 1997, 1999). They
appear to be involved neither in the perception of acute pain
nor in the development and maintenance of nerve injury-
associated hypersensitive painful states in animal models
(Chaplan et al 1994; Yamamoto and Sakashita 1998). The
antinociceptive profiles of subtype-selective calcium
channel blockers may reflect the involvement of distinct
populations of primary or secondary sensory neurons in the
transmission and processing of different types of pain
signals. This is a plausible contributory factor because
although both N-type and P/Q-type calcium channels are
found in the dorsal horn of the spinal cord, they actually
display complementary neuronal distributions, with the same
nerve terminal rarely containing both subtypes.
In summary, potent antinociceptive effects of ziconotide
have been observed in several animal models of pain under
a variety of dosing regimens, including acute and chronic
administration. The demonstration that ziconotide retains
its potent antinociceptive efficacy during chronic
administration provides convincing evidence that, unlike
the opioids, this drug is not associated with the development
of tolerance. This observation has important implications
for the long-term therapeutic use of ziconotide in the
treatment of pain in patients. The experimental evidence
also suggests that N-type calcium channels expressed at
multiple sites along the pain pathway are functionally
important in the transmission of pain signals. These locations
may include the peripheral site of nerve injury, where the
N-type calcium channels appear to be involved in the
generation of persistent spontaneous neuronal activity under
conditions of nerve injury. In addition, N-type calcium
channels are important for the transmission of incoming
nociceptive signals to secondary sensory neurons in the
spinal cord whereas those in the rostral ventromedial
medulla may be involved in the activation of descending
pain facilitatory systems that have been shown to contribute
to the maintenance of neuropathic pain states.Neuropsychiatric Disease and Treatment 2007:3(1) 79
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Ziconotide: clinical studies
The development path to regulatory approval of intrathecal
ziconotide involved three large randomized, double-blind,
placebo-controlled Phase 3 clinical trials that established
the safety and analgesic efficacy of this drug in more than
600 patients (see Table 4A). All of the patients in these trials
were suffering from severe chronic pain of malignant and/
or non-malignant origins (Staats et al 2004; Rauck et al 2006;
Wallace et al 2006) and in order for them to be accepted
into the trials, it was necessary that their pain was
inadequately controlled by other analgesic drugs, including
opioids. These clinical trials evaluated the analgesic efficacy
of ziconotide under chronic dosing paradigms (up to 3
weeks) in order to determine the potential for this drug to
develop tolerance. In addition to these pivotal trials, a smaller
placebo-controlled clinical trial demonstrated analgesic
efficacy of ziconotide in a post-surgical setting (see Table
4A) and a number of open-label studies showed that
ziconotide can be an effective therapy in the treatment of
neuropathic pain (see Table 4B). There are several
previously published reviews available that discuss the
clinical experiences with ziconotide (Jain 2000; Heading
2001; Doggrell 2004; Miljanich 2004; Lyseng-Williamson
and Perry 2006; Staats 2006).
The first pivotal trial with ziconotide involved patients
with chronic pain due to cancer or AIDS (Staats et al 2004).
In this trial, 68 patients received ziconotide by continuous
intrathecal infusion for an initial 5- to 6-day period, followed
by a maintenance period for those who responded to
treatment. The starting dose of ziconotide was low (≤0.1 or
0.4 μg/h), although it could be increased frequently (at 12-
or 24-hour intervals) either until satisfactory pain relief was
achieved, the maximum dose of 2.4 μg/h was reached or
adverse events were reported. Moderate to complete pain
relief was achieved for most patients during the initial phase,
with an average 53% reduction in pain scores, as estimated
on a visual analog scale of pain intensity (VASPI).
Importantly there was no loss of analgesic efficacy during
the maintenance phase, suggesting that humans do not
develop tolerance to ziconotide. Adverse events were
observed more frequently in the ziconotide group than in
the placebo group and in general, their occurrence was
reduced either by initiating the drug infusion at lower doses
or by using smaller or less frequent dose increments.
The second pivotal trial evaluated the safety and efficacy
of ziconotide in patients with chronic non-malignant (mostly
neuropathic) pain (Wallace et al 2006). In this trial, 169
patients received ziconotide beginning at a low dose (≤0.1
or 0.4 μg/h) and during the subsequent several days, the dose
could be doubled at 24-hour intervals either until satisfactory
pain relief was achieved, the maximum dose was reached
(2.4 or 7.0 μg/h, depending on starting dose) or adverse
events were experienced. As in the first trial, patients
receiving ziconotide experienced moderate to complete pain
relief, although the average reduction in VASPI scores was
lower in this second trial. Responders continued to receive
drug during the maintenance period, during which the
efficacy of ziconotide was maintained. Again, adverse events
could be resolved by reducing the dose or frequency of
titration or by discontinuation of the drug.
The third pivotal trial evaluated the safety and efficacy
of ziconotide in 220 patients with intractable severe chronic
pain, the majority of which was neuropathic (Rauck et al
2006). This trial was conducted in response to regulatory
concerns that were raised about the high incidence and
severity of the adverse events as well as the high rate of
patient drop-out during the first two trials. Therefore the
design of this third trial differed from the earlier trials in
several important aspects: (1) a slower titration schedule
was employed (increments of 0.1 μg/h no more frequently
than every 24 hours); (2) a lower maximum dose was
allowed (0.9 μg/h); and (3) the trial length was longer (3
weeks). Significant pain relief was achieved in the majority
of patients receiving ziconotide and the average
improvement in VASPI scores was estimated to be 15%.
The magnitude of this reduction was smaller than what was
reported in the previous trials and this seems to be consistent
with the lower doses used. In addition, the patients in the
ziconotide group consumed 24% less opioid drug compared
to the placebo group. Adverse events were experienced at
low therapeutic doses of ziconotide in this trial, but most of
these were rated as mild or moderate and were slow to
develop after the drug infusion was initiated.
A relatively small clinical trial evaluated the ability of
ziconotide to reduce post-operative pain arising from major
surgery (Atanassoff et al 2000). Low dose (0.7 μg/h) or high
dose (7.0 μg/h) ziconotide was given to patients undergoing
total abdominal hysterectomy, radical prostatectomy, or total
hip replacement. In this trial, ziconotide infusion was
initiated before surgical incision and was continued for up
to 72 hours post-operatively. For those patients who received
ziconotide, significant pain relief was experienced and
morphine consumption was reduced. Side-effects, such as
dizziness, blurred vision, nystagmus, and sedation, appearedNeuropsychiatric Disease and Treatment 2007:3(1) 80
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to be more severe in the high-dose drug group and they
resolved after discontinuation of the drug.
A number of open-label clinical trials have also been
conducted with ziconotide. In one of the earliest reported
trials, ziconotide was administered to a patient who had been
suffering for more than 20 years from intractable de-
afferentation pain as a result of brachial plexus avulsion
and limb amputation (Brose et al 1997). This patient was
given ziconotide by continuous, constant rate, intrathecal
infusion and complete pain relief was achieved, even after
the dose was lowered to 2 ng/kg hourly to alleviate the
patient’s side-effects of dizziness, blurred vision, and
nystagmus. Another trial evaluated the analgesic efficacy,
safety, and pharmacokinetic properties of intrathecal
Table 4 Summary of clinical trials conducted with ziconotide
A. Double-blind, blacebo-controlled studies
Study report Ziconotide dosing Clinical Observations
Intractable severe pain • 68 patients received ziconotide and 40 received • Ziconotide provided moderate to complete pain relief.
due to cancer or AIDS placebo Pain scores were reduced by an average of 53% during
(Staats et al 2004) • Ziconotide was administered by continuous the initial phase, with no loss of efficacy during the
intrathecal infusion at 0.1–2.4 μg/h or 0.4–7.0 μg/h maintenance phase
for up to 6 days, followed by a 5-day maintenance • Adverse events included dizziness, nystagmus, nausea,
phase for responders postural hypotension, somnolence, and confusion
Intractable • 169 patients received ziconotide and 86 received • Ziconotide provided moderate to complete pain relief.
non-malignant severe placebo Pain scores were reduced by an average of 31% during
chronic pain • Ziconotide was administered by continuous the initial phase, with no loss of efficacy during the
(Wallace et al 2006) intrathecal infusion at 0.4–7.0 μg/h or 0.1–2.4 μg/h maintenance phase
for 6 days, followed by a 5-day maintenance phase • Adverse events included dizziness, nausea, nystagmus,
for responders and abnormal gait
Intractable severe • 112 patients received ziconotide and 108 received • Ziconotide provided significant pain relief. Pain scores
chronic pain placebo were reduced by an average of 15% and there was
(Rauck et al 2006) • Ziconotide was administered by continuous decreased consumption of opioids
intrathecal infusion at 0.1–0.9 μg/h for up to • Adverse events included dizziness, confusion, ataxia,
3 weeks abnormal gait and memory impairment
Post-operative pain • 18 patients received ziconotide and 12 received • Ziconotide provided significant pain relief at both low
(Atanassoff et al 2000) placebo and high doses. Pain scores were reduced by an average
• Ziconotide was administered by continuous of 50% and there was decreased consumption of
intrathecal infusion at 0.7 or 7.0 μg/h for 48–72 h morphine
• Adverse events included dizziness, blurred vision,
nystagmus, and sedation
B. Open-label studies
Study report Ziconotide dosing, efficacy and adverse events
Intractable • One patient received ziconotide
de-afferentation pain • Ziconotide was administered by continuous intrathecal infusion at 0.3–3 ng/kg/h for 8 days
(Brose et al 1997) • Complete pain relief was experienced with 2–3 ng/kg/h – the patient’s pain score was reduced from 85 mm
to 0 mm
• Adverse events included dizziness, blurred vision, and lateral gaze nystagmus
Neuropathic pain • 22 patients received ziconotide
(Wermeling • Ziconotide was administered by intrathecal infusion of 1, 5, 7.5, or 10 μg over 1 hour
et al 2003) • Analgesia was dose-dependent, being greatest in the 7.5 μg group and lowest in the 1 μg group
• Adverse events included myasthenia, dizziness, headache, nausea, abnormal gait, and somnolence
Neuropathic pain • Patient 1 received a single epidural dose of ziconotide at 5 μg. Significant pain relief was achieved, with the
(Wermeling and patient’s pain score reduced from 85 mm to <10 mm.  Adverse events included light-headedness, headache, and
Berger, 2006) somnolence
• Patient 2 received a single epidural dose of ziconotide at 10 μg. Complete pain relief was experienced, with the
patient’s pain score reduced from 68 mm to 0 mm.  Adverse events included decreased blood pressure,
somnolence, itching, nausea, and headache
• Patient 3 received continuous intrathecal infusion of ziconotide at 0.3–100 ng/kg/h for up to 34 days. Ziconotide
delivered significant pain relief at 5–12 ng/kg/h, with the patient’s pain score reduced from 67 mm to 4 mm.
Adverse events included sedation, confusion, memory impairment, slurred speech, and double vision.Neuropsychiatric Disease and Treatment 2007:3(1) 81
Zicotinamide for pain treatment
ziconotide in patients with chronic neuropathic pain
(Wermeling et al 2003). Ziconotide was infused over a 1-
hour period at doses of 1, 5, 7.5, or 10 μg. The analgesic
efficacy of ziconotide was dose-related and was correlated
with drug exposure in the cerebrospinal fluid. Moreover,
efficacy developed rapidly (within 1 hour of initiation of
drug infusion) and lasted for up to 48 hours. Most of the
adverse events in this study were mild to moderate and
serious events were only reported in the highest dose group.
Another open-label trial evaluated the ability of ziconotide
to relieve the symptoms of long-standing neuropathic pain
of various origins in 3 patients (Wermeling and Berger
2006). Single dose administration (in 2 patients) or
continuous infusion (in 1 patient) of ziconotide alleviated
the pain considerably. The patients who received the single
dose reported only mild side-effects, whereas the patient
who received continuous infusion experienced more severe
neurological side-effects. Interestingly, this patient could
feel the imminent side-effects and was able to avoid them
by reducing the rate of drug infusion. Regarding the
pharmacokinetic profile of ziconotide in the cerebrospinal
fluid of humans, the measured t½ is around 4½ hours, which
is similar to the slow component of drug elimination that
has been observed in rats and monkeys (Bowersox et al
1997). Ziconotide was not detectable in the plasma of the
majority of patients, supporting the idea that this drug cannot
easily cross the blood–brain barrier.
In summary, intrathecal ziconotide is a novel, potent and
long-lasting analgesic therapy that can be used for the
symptomatic relief of severe chronic pain of malignant and
non-malignant origins. It is also effective for the prevention
of surgically-induced pain. Since ziconotide is administered
intrathecally to patients, it is tempting to speculate that its
therapeutic mechanism of action primarily involves block
of pre-synaptic N-type calcium channels in the spinal cord,
leading to a reduction in the release of pronociceptive
neurotransmitters from primary afferent nerve terminals and
reduced synaptic excitation of secondary sensory neurons
in the dorsal horn. Importantly, ziconotide is non-addictive
and does not appear to induce the development of tolerance.
Therefore it represents an analgesic therapy that is suitable
for long-term use and in at least 1 case, a patient continued
taking the drug for more than 7 years. Despite the use of an
infusion pump to deliver drug directly into the intrathecal
space, it is very difficult to predict or control the local
concentration of ziconotide that can access the N-type
calcium channels located on the central terminals of the
primary sensory neurons in the dorsal horn. Therefore the
optimal dose of drug needs to be determined empirically.
Nevertheless, the therapeutic index of ziconotide tends to
be low and adverse events (primarily psychiatric and
neurological) may be experienced, particularly if the drug
is infused rapidly, a high dose is given or the dose is escalated
too frequently. However, the good news is that when adverse
events are experienced, they usually resolve when the dose
is lowered or the frequency of dose escalation is reduced.
In order to minimize the incidence and severity of adverse
events in new patients, the manufacturer recommends a
“start low, go slow” approach to the use of ziconotide. The
current recommendation is to initiate the infusion at a low
dose of ≤0.1 μg/h and to titrate the dose upwards no more
frequently than 2–3 times/week. This approach has been
shown to produce fewer serious adverse events and to reduce
the incidence of drug discontinuation by patients.
Future prospects and concluding
remarks
Ziconotide represents a great achievement for current pain
therapy but despite its potent analgesic efficacy there
remains significant opportunity for improvement. The
opportunity derives primarily from the peptidic nature of
the drug and its requirement for intrathecal administration
in order to yield analgesic efficacy with reduced potential
for systemic and central nervous system side-effects.
Consequently, drug discovery researchers are considering
various approaches to identify and develop novel orally
active, N-type calcium channel-selective blockers that have
the potential to be superior to ziconotide.
High analgesic efficacy and improved safety and
tolerability, relative to both ziconotide and the opioids, are
essential properties of a next generation N-type calcium
channel blocking drug. This goal could be achieved by
exploring approaches to identify compounds that display
greater selectivity for sensory neuron-specific splice variants
of the N-type calcium channel and/or that possess a use-
dependent mechanism of calcium channel block. Regarding
the former approach, multiple kinetically distinct splice
variants of the calcium channel α1B subunit are known to
exist, some of which appear to be exclusive to peripheral
neurons (Lin et al 1997, 1999). In particular, a dorsal root
ganglion-specific variant was recently identified in rat (Bell
et al 2004; Castiglioni et al 2006) and this discovery offers
hope that human N-type calcium channels might also exhibit
sensory neuron-specific splice variants that could be targeted
selectively in the search for safer and more efficacious pain
therapeutics. Regarding use-dependent N-type calciumNeuropsychiatric Disease and Treatment 2007:3(1) 82
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channel blockers, one idea is to identify compounds that
bind preferentially to open and/or inactivated states of the
channel (Winquist et al 2005). If successful, this approach
is likely to lead to the identification of molecules that might
inhibit calcium influx more effectively during high-
frequency neuronal firing, which occurs in hypersensitive
pain states, and less effectively during low-frequency
neuronal firing. The hope is that novel molecules displaying
a use-dependent mechanism of action will offer both high
analgesic efficacy and an improved therapeutic index
relative to ziconotide. Neuromed Pharmaceuticals is
pioneering efforts in this arena and recently they have
partnered with Merck & Co. to develop NMED-160, an
orally-available, use-dependent blocker of N-type calcium
channels that is in Phase 2 clinical trials for a variety of
pain conditions. In pre-clinical testing, this molecule
displayed a broad efficacy profile in animal models of
neuropathic and inflammatory pain and also had a good
safety profile (Snutch et al 2003; Snutch 2004). However,
it still remains to be shown that this drug is analgesic in
patients with severe chronic pain.
Improved ease of administration is also a desirable
property of a novel drug that could negate the requirement
for intrathecal therapy that currently hinders widespread
testing and use of ziconotide. Indeed, if a novel N-type
calcium channel blocker could be delivered systemically
then this would not only enable easier delivery to existing
patients but could also increase the size of the patient
population that stands to benefit from analgesia by this
mechanism. An additional benefit of systemic delivery
would be to reduce the risk of infection that is associated
with a surgically implanted drug delivery device. Although
it is theoretically possible to identify peptidic molecules that
can cross the blood brain barrier, eg, the ziconotide analog
SNX-194 (Newcomb et al 2000) the development hurdles
would be difficult to overcome due to the access such a
molecule would have to N-type calcium channels throughout
the entire nervous system, including the sympathetic neurons
that are involved in the control of blood pressure. In addition,
due to their widespread distribution in the endocrine system
(Sher et al 2003; Olsen et al 2005; Takahashi et al 2005), it
must be appreciated that drugs targeting N-type calcium
channels could have myriad effects on multiple organs that
rely on these channels to carry out their normal physiological
functions. Therefore based on current knowledge, a
structurally novel, orally active small molecule with a use-
dependent mechanism of action is considered to be the most
desirable target profile for a next generation N-type calcium
channel blocking drug for use in the treatment of severe
pain.
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